Press coverage about Ocata Therapeutics (NASDAQ:OCAT) has trended somewhat negative this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ocata Therapeutics earned a media sentiment score of -0.22 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 41.420066728672 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Ocata Therapeutics (OCAT) opened at $8.47 on Friday. Ocata Therapeutics has a 12 month low of $3.06 and a 12 month high of $8.71.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at

About Ocata Therapeutics

Ocata Therapeutics, Inc, formerly Advanced Cell Technology, Inc, is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration.

Insider Buying and Selling by Quarter for Ocata Therapeutics (NASDAQ:OCAT)

Receive News & Ratings for Ocata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.